FDA (Food and Drug Administration) Drug Approval Process Training Course: Comprehensive Programme Covering Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (LIVE ONLINE EVENT/ON-DEMAND)
21 nov. 2024 06h08 HE
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union: 2-Day Online Training Course (October 3-4, 2024)
03 juil. 2024 11h18 HE
|
Research and Markets
Dublin, July 03, 2024 (GLOBE NEWSWIRE) -- The "Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course" conference has been added to ResearchAndMarkets.com's offering. ...
Muscular Dystrophy Association Applauds Expanded US FDA Approval of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy Patients Ages 4 and Above
20 juin 2024 18h42 HE
|
Muscular Dystrophy Association
New York, June 20, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the U.S. Food and Drug Administration’s expanded approval of ELEVIDYS (delandistrogene...
Russia and the Eurasian Union Pharmaceutical Regulatory Affairs Training Course (ONLINE EVENT: June 24-27, 2024/On-Demand)
18 juin 2024 11h02 HE
|
Research and Markets
Dublin, June 18, 2024 (GLOBE NEWSWIRE) -- The "Pharmaceutical Regulatory Affairs in Russia and the Eurasian Union Training Course" conference has been added to ResearchAndMarkets.com's offering. ...
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
30 mai 2024 13h41 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Muscular Dystrophy Association’s Funding of Foundational Research Leads to New FDA Approved Treatment Duvyzat (givinostat) for Duchenne Muscular Dystrophy
21 mars 2024 19h45 HE
|
Muscular Dystrophy Association
New York, March 21, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association’s funding of foundational research leads to new drug approval by the US Food and Drug Administration (FDA) of Duvyzat...
The FDA (Food and Drug Administration) Drug Approval Process, 2 Day Virtual Training Course
22 janv. 2024 11h43 HE
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" has been added to ResearchAndMarkets.com's offering. The US is the...
Mastering the FDA Drug Approval Process: Strategies for Success in the US Pharmaceutical Market (February 6-7, 2024)
02 nov. 2023 07h28 HE
|
Research and Markets
Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "The FDA (Food and Drug Administration) Drug Approval Process Training Course" conference has been added to ResearchAndMarkets.com's offering. The US...
Muscular Dystrophy Association-Supported Drug AGAMREE® (vamorolone) Approved for the Treatment of Duchenne Muscular Dystrophy by the FDA
26 oct. 2023 16h24 HE
|
Muscular Dystrophy Association
New York, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique...
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
26 oct. 2023 15h19 HE
|
Catalyst Pharmaceuticals, Inc.
AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for...